美国临床肿瘤学会多基因检测临床实践指南更新及临床意义

doi:10.6040/j.issn.1671-7554.0.2017.1074

摘要/Abstract

摘要： 近年来,随着多基因检测在早期浸润性乳腺癌患者辅助化疗决策中的使用,早期浸润性乳腺癌的综合诊治理念已在细化解剖学分期,精确掌握宏观肿瘤负荷的基础上,跨越到结合基因检测信息、分析肿瘤生物学特性,实施个体化治疗以达到损伤最小化的新阶段。2017年7月《临床肿瘤学杂志》(Journal of Clinical Oncology, JCO)刊登美国临床肿瘤学会(American Society of Clinical Oncology, ASCO)多基因检测临床指南更新内容,其中,针对不同人群多基因检测提出推荐意见,重点提高了MammaPrint^®临床应用的推荐强度,旨在科学指导临床医生合理地制定治疗决策,避免过度医疗。

关键词: 乳腺癌, 美国临床肿瘤学会, 多基因检测, MammaPrint^®,

Abstract: In recent years, multigene tests have been recommended to guide decisions on the need of adjuvant chemotherapy for patients with early-stage breast cancer. The comprehensive strategy of early-stage breast cancer has come into an era, when both anatomic tumor burden and multigene test results should be taken into consideration to gain a better understanding of tumor biology and personalized treatment, in order to minimize toxic effects. In July 2017, the Journal of Clinical Oncology(JCO)published the new version of the clinical practice guideline of American Society of Clinical 山东大学学报 (医学版)56卷1期 -刘荫华,等.美国临床肿瘤学会多基因检测临床实践指南更新及临床意义 \=-Oncology(ASCO)on the use of biomarkers to guide therapeutic decision for breast cancer. The guideline provided criteria of clinical utility for different patient groups, and focused on the recommendation of MammaPrint^®with evidence of high quality, leading to reasonable decision-making for clinicians to avoid overtreatment.

Key words: Breast cancer, American Society of Clinical Oncology, Multigene tests, MammaPrint^®,

中图分类号:

R737.9

刘荫华,赵婧祎,辛灵. 美国临床肿瘤学会多基因检测临床实践指南更新及临床意义[J]. 山东大学学报 (医学版), 2018, 56(1): 1-5.

LIU Yinhua, ZHAO Jingyi, XIN Ling. Focused updates of American Society of Clinical Oncology Guideline on the use of multigene tests in clinical practice for breast cancer[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 1-5.

参考文献

[1] Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update[J]. J Clin Oncol, 2017, 35(24): 2838-2847.
[2] Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2015, 26(Suppl~5): 8-30.
[3] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. V.2.2017. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
[4] Liedtk C, Thil M, Jackisch C, et al. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2017[J]. Breast Care, 2017, 12(3): 172-183.
[5] vant Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002, 415(6871): 530-536.
[6] van de Vijver MJ, He YD, vant Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer[J]. N Engl J Med, 2002, 347: 1999-2009.
[7] Buyse M, Loi S, vant Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer[J]. J Natl Cancer Inst, 2006, 98(17): 1183-1192.
[8] Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Annals of Oncol, 2011, 22(8): 1736-1747.
[9] Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial[J]. Nat Clin Pract Oncol, 2006, 3(10): 540-551.
[10] Cardoso F, Vant Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial[J]. J Clin Oncol, 2008, 26(5): 729-735.
[11] Cardoso F, vant Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8): 717-729.
[12] Adjuvant! Online Web Site. http://www.adjuvantonline.com.
[13] Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York: Springer, 2016.
[14] Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer[J]. J Clin Oncol, 2001, 19(4): 980-991.
[15] Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study[J]. Lancet Oncol, 2009, 10(11): 1070-1076.
[16] Hajage D, de Rycke Y, Bollet M, et al. External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement[J]. PLoS One, 2011, 6(11): e27446. doi: 10.1371/journal.pone.0027446. Epub 2011 Nov 8.
[17] Campbell HE, Taylor MA, Harris AL, et al. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom[J]. Br J Cancer, 2009, 101(7): 1074-1084.
[18] Olivotto IA, Bajdik CD, Ravdin PM, et al. Population based validation of the prognostic model ADJUVANT! for early breast cancer[J]. J Clin Oncol, 2005, 23(12): 2716-2725.
[19] Users Guide for Adjuvant! Version 8.0, Dec 2005.
[20] Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers(EGTM)[J]. Eur J Cancer, 2017, 75: 284-298. doi: 10.1016/j.ejca.2017.01.017. Epub 2017 Feb 28.
[21] Oncotype DX^® Web Site. http://www.oncotypedx.com.
[22] EndoPredict^® Web Site.http://www.endopredict.com/en/home.html.
[23] Prosigna^®, PAM 50 Web Site. https://www.nanostring.com/diagnostics/prosigna.
[24] Breast Cancer Index Web Site. https://www.breastcancerindex.com.
[25] 江泽飞, 许凤锐. 乳腺癌精准医学: 热潮中的冷思考[J]. 中华外科杂志, 2017, 55(2): 90-94. JIANG Zefei, XU Fengrui. Calm thinking for precision medicine of breast cancer in the boom[J]. Chinese Journal of Surgery, 2017, 55(2): 90-94.

相关文章 15

[1]	古春青,郭睿思,周勤勤,刘恒辉,巴婉玉,孙士玲,王冰,郑玉玲,吴宿慧. 基于网络药理学和动物实验探讨酸枣仁-远志药对治疗乳腺癌相关性失眠的作用机制[J]. 山东大学学报 (医学版), 2026, 64(1): 99-108.
[2]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[3]	王雪梅,杨豪,宋洋,程世超,张婷婷,王艳春. 抗糖尿病药物与女性恶性肿瘤的因果关联:一项两样本孟德尔随机化分析[J]. 山东大学学报 (医学版), 2025, 63(6): 67-77.
[4]	赵芸慕兰,高海燕. 中、高危分化型甲状腺癌患者术后 ¹³¹I治疗反应及预后的影响因素[J]. 山东大学学报 (医学版), 2025, 63(2): 21-28.
[5]	徐年兴,魏东,乔俊杰,战炳炎. CD8⁺、IL-6和PaO₂对不可切除Ⅲ_B/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[6]	余之刚,郑超. 乳腺癌多学科诊疗的现状、挑战与创新模式[J]. 山东大学学报 (医学版), 2025, 63(1): 1-9.
[7]	山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16.
[8]	程跃启,王斐,于理想,郑超,余之刚. 曲妥珠单抗致HER2阳性乳腺癌患者心脏毒性的研究进展[J]. 山东大学学报 (医学版), 2025, 63(1): 17-24.
[9]	王敏, 李习平, 檀军, 邱梅, 侯泽宇, 田莹, 罗鸿莹, 范超文, 齐玲, 俞琦, 谢薇. 慢病毒载体介导Gag-Caspase-8诱导三阴性乳腺癌原代细胞凋亡及S期阻滞[J]. 山东大学学报 (医学版), 2025, 63(1): 25-34.
[10]	张洁,张芳芳,王靖楠,李泽宇,宋颖,李娜. circ_0000144在乳腺癌中的表达及其对乳腺癌细胞增殖、迁移和侵袭能力的影响[J]. 山东大学学报 (医学版), 2025, 63(1): 35-42.
[11]	宋雅雯,郭联涛,孔德光,孙圣荣. VTCN1导致HR+乳腺癌预后不良及内分泌治疗耐药[J]. 山东大学学报 (医学版), 2025, 63(1): 43-59.
[12]	刘晶晶,庞婧,赵晓丹,林昕,付敏,陈静静. 基于乳腺X线摄影及DCE-MRI机器学习模型预测乳腺癌新辅助治疗后病理完全缓解:双中心研究[J]. 山东大学学报 (医学版), 2025, 63(1): 60-72.
[13]	孙婧,杨瑞敏,王聪,张月,罗兵. 基于术前超声、炎症指标及超声影像组学联合模型预测乳腺癌腋窝淋巴结转移[J]. 山东大学学报 (医学版), 2025, 63(1): 73-80.
[14]	李永,崔书君,杨飞,张凡,殷晓霞. 基于增强MRI的亚区域影像组学模型可预测乳腺癌患者新辅助化疗后的病理完全反应[J]. 山东大学学报 (医学版), 2025, 63(1): 81-89.
[15]	袁宗怀,潘广晔,迟曰梅,安传国,张永刚. 孟德尔随机化分析低级别浆液性卵巢癌与乳腺癌的因果关系[J]. 山东大学学报 (医学版), 2025, 63(1): 99-107.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed